Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

Lucy Thorne(University College London), Nevan J. Krogan(QB3), Mahdad Noursadeghi(Institute of Infection and Immunity), Kirsten Obernier(QB3), Danish Memon(European Bioinformatics Institute), Adrian Pelin(Gladstone Institutes), Margaret Soucheray(Gladstone Institutes), Natalia Jura(QB3), Lorena Zuliani‐Alvarez(Gladstone Institutes), Bhavya Harjai(Gladstone Institutes), Jyoti Batra(Gladstone Institutes), Ajda Rojc(Gladstone Institutes), Pedro Beltrão(SIB Swiss Institute of Bioinformatics), Mehdi Bouhaddou(QB3), Matthew V. X. Whelan(University College London), Hannes Braberg(Rapt Therapeutics (United States)), Jane Turner(University College London), Greg J. Towers(University College London), Ann‐Kathrin Reuschl(University College London), Kuei‐Ho Chen(Gladstone Institutes), Myra Hosmillo(University of Cambridge), Benjamin J. Polacco(QB3), Kevan M. Shokat(Howard Hughes Medical Institute), Alicia Richards(Wayne State University), Clare Jolly(Institute of Infection and Immunity), Aminu S. Jahun(Department of Virology), Danielle L. Swaney(Gladstone Institutes), Manisha R. Ummadi(Gladstone Institutes), Joseph Hiatt(Gladstone Institutes), Klim Verba(University of California, San Francisco), Adolfo García‐Sastre(Office of Infectious Diseases), Jacqueline M. Fabius(University of California, San Francisco), Ian Goodfellow(University of Cambridge)
bioRxiv (Cold Spring Harbor Laboratory)
June 7, 2021
Cited by 107


Related Papers